Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Marinus Pharma CS (MRNS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE Capital Corporation (NYSE:STOR),...

STOR : 26.10 (-0.46%)
MCK : 144.03 (-1.91%)
MVIS : 1.58 (-5.39%)
IGT : 27.36 (-0.69%)
ALNY : 98.97 (+0.89%)
MRNS : 6.02 (+15.11%)
Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec Medical

If you want a free Stock Review on MNKD, MRNS, MRTX, and ONCS sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on MannKind Corp. (NASDAQ: MNKD), Marinus...

ONCS : 1.59 (+1.27%)
MRTX : 39.05 (+1.83%)
MNKD : 1.94 (unch)
MRNS : 6.02 (+15.11%)
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders,...

MRNS : 6.02 (+15.11%)
Report: Developing Opportunities within Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and The Charles Schwab -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Discovery Communications, Inc....

CFG : 41.54 (-0.60%)
DISCK : 21.24 (-0.47%)
SCHW : 58.14 (-1.34%)
OTIC : 4.40 (-2.22%)
MRNS : 6.02 (+15.11%)
WPG : 7.45 (-1.06%)
Marinus Pharmaceuticals to Attend Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...

MRNS : 6.02 (+15.11%)
Today's Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower,...

IMUC : 0.27 (unch)
MRNS : 6.02 (+15.11%)
Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...

MRNS : 6.02 (+15.11%)
Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.

NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Marinus Pharmaceuticals closed up 14% higher on Thursday after SAGE Therapeutics revealed positive clinical trial data for a postpartum depression...

SAGE : 158.17 (+1.46%)
OTIC : 4.40 (-2.22%)
MRNS : 6.02 (+15.11%)
Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink Genetics

If you want a Stock Review on CYTX, SRNE, MRNS, or NLNK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com observes the...

SRNE : 7.95 (+5.30%)
CYTX : 2.39 (-8.08%)
MRNS : 6.02 (+15.11%)
NLNK : 5.40 (+1.31%)
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today...

MRNS : 6.02 (+15.11%)
Today's Research Report Coverage on Biotech Stocks -- Marinus Pharma, NewLink Genetics, Akcea Therapeutics, and Amgen

If you want a Stock Review on MRNS, NLNK, AKCA, or AMGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Friday, September 29, 2017, the NASDAQ Composite,...

AKCA : 23.60 (+4.56%)
AMGN : 177.96 (-1.10%)
MRNS : 6.02 (+15.11%)
NLNK : 5.40 (+1.31%)
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals

PALM BEACH, Florida, September 26, 2017 /PRNewswire/ --

ACRX : 3.40 (+7.94%)
BCRX : 5.95 (+0.34%)
NVAX : 1.72 (+1.18%)
MRNS : 6.02 (+15.11%)
MBRX : 1.69 (+4.97%)
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals

One attractive position with regards to the biotech industry is that there are practically always a few industry leaders on weekly basis that are achieving new milestones and accomplishing key developments...

ACRX : 3.40 (+7.94%)
BCRX : 5.95 (+0.34%)
NVAX : 1.72 (+1.18%)
MRNS : 6.02 (+15.11%)
MBRX : 1.69 (+4.97%)
Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward...

MRNS : 6.02 (+15.11%)
Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of...

MRNS : 6.02 (+15.11%)
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75...

MRNS : 6.02 (+15.11%)
Marinus Pharmaceuticals Announces Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is...

MRNS : 6.02 (+15.11%)
Biotechs Ramp up Clinical Trial Programs as FDA Looks at More Efficient Drug Development Programs

PALM BEACH, Florida, September 13, 2017 /PRNewswire/ --

ALDX : 8.73 (+0.29%)
TEVA : 21.63 (+2.27%)
FWP : 3.11 (+6.51%)
MRNS : 6.02 (+15.11%)
MBRX : 1.69 (+4.97%)
Biotechs Ramp up Clinical Trial Programs as FDA Looks at More Efficient Drug Development Programs

The hope of new measures for the FDA to advance the regulatory path for drug development is forging ahead incorporating relatively swift pivotal data in seeking accelerated approvals. FDA commissioner...

ALDX : 8.73 (+0.29%)
TEVA : 21.63 (+2.27%)
FWP : 3.11 (+6.51%)
MRNS : 6.02 (+15.11%)
MBRX : 1.69 (+4.97%)
Marinus Stock Surges on Successful Phase II Epilepsy Study

Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.

ADVM : 6.15 (unch)
ACAD : 17.47 (+2.76%)
ADRO : 8.25 (+0.61%)
MRNS : 6.02 (+15.11%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar